Skip to main content
In-Vitro Research Only
Sign in

ACE-031: High-Affinity ActRIIB Ligand Traps and Myostatin Inhibition

Compliance & Laboratory Safety Team18th Sep 2026

ACE-031: High-Affinity ActRIIB Ligand Traps and Myostatin Inhibition
AT A GLANCE · KEY RESEARCH SUMMARY

What You Need to Know About ACE-031: High-Affinity ActRIIB Ligand Traps and Myostatin Inhibition

Primary Focus
ACE-031 is a laboratory fusion protein designed to study how blocking myostatin and related signalling molecules affects skeletal muscle growth and tissue remodelling.
Molecular Profile
A soluble recombinant fusion protein combining the extracellular binding domain of the human activin receptor type IIB (ActRIIB) with the Fc portion of human immunoglobulin G1 (IgG1).
Fridge Storage
2°C–8°C (12–24 Months)
Quality Standard
99%+ HPLC Verified
  • Researchers and curious readers explore ACE-031 to understand how lifting the natural biological brakes on muscle growth alters fibre size and overall lean mass in laboratory models.
  • This compound works like a molecular sponge in the bloodstream, trapping myostatin and similar proteins before they can attach to real muscle cell receptors and tell the muscle to stop growing.
  • Published studies in preclinical models observed rapid increases in skeletal muscle volume, improved force generation, and beneficial changes in bone density and fat metabolism.
  • Early human research programmes were halted after investigators noted off-target effects on small blood vessels, such as nosebleeds and skin telangiectasias, linked to blocking bone morphogenetic protein nine (BMP9).

How Decoy Receptors Pause the Cellular Brakes on Tissue Growth

ACE-031 works as a soluble decoy receptor that catches myostatin in the fluid outside cells before the protein can tell muscle fibres to stop growing. By soaking up these braking signals early, the compound leaves the natural cellular switches for tissue remodelling and structural recovery switched on in laboratory models.

In normal biology, skeletal tissue does not grow without limits. The body uses a group of proteins called the transforming growth factor-beta superfamily to keep muscle size in check. The best-known member of this group is myostatin, also called growth differentiation factor eight. Myostatin travels through the bloodstream looking for a specific docking station on the surface of muscle cells known as the activin receptor type IIB, or ActRIIB. When myostatin clicks into this receptor, it sends a chemical message inside the cell that slows down protein building and halts the birth of new muscle fibres.

Scientists engineered ACE-031 as a fusion protein by taking the outer, catching portion of the ActRIIB receptor and joining it to the stable tail end of a standard human antibody. Because it floats freely in the extracellular space, ACE-031 acts like a sponge. It binds to myostatin, activin A, and growth differentiation factor eleven before they ever reach the real muscle cell wall.

When those negative regulators are trapped out in the open, the real ActRIIB docking stations stay empty. Inside the cell, the Smad2 and Smad3 messenger proteins remain quiet instead of blocking growth genes. Preclinical models show that lifting this natural brake allows satellite cells to wake up, fuse with existing fibres, and support faster structural recovery after physical strain.

RELATED UK CATALOGUE

This page is not tied to one stocked vial. Start with the bundles hub, BPC-157, or GHK-Cu — each is in stock for next-day UK dispatch.

Browse Full UK Peptide Catalogue →

Tracking ActRIIB Signalling Shifts from Hours to Weeks in Preclinical Models

In laboratory models, the gap between the first biochemical binding event and visible structural tissue remodelling follows a clear two-stage calendar. Because ACE-031 is built on an antibody-like backbone, it stays active in biological fluids much longer than small, fast-clearing short chains.

During the first twenty-four to seventy-two hours after a measured level is introduced to an experimental system, the changes are purely chemical. The fusion protein circulates and rapidly binds free myostatin and related ligands in the surrounding fluid. Published studies tracking blood markers in preclinical models show a sharp drop in free circulating myostatin within the first two days. At the same time, intracellular phosphorylation of Smad2 and Smad3 drops off, lifting the block on ribosomal protein synthesis. You cannot see any physical change in tissue size during this early window, even though the gene expression profile inside the muscle fibres has already shifted toward growth and repair.

Structural changes take much longer to appear because cells have to physically build and lay down new contractile proteins like actin and myosin. In published studies using rodent and primate laboratory models, measurable increases in individual muscle fibre cross-sectional area begin to show up between week two and week four. Noticeable gains in overall lean tissue mass and grip strength readouts typically peak between four and eight weeks of continuous observation.

Researchers also note that because ACE-031 traps multiple ligands beyond just myostatin, including bone morphogenetic proteins, extended observation windows are necessary to watch how non-muscle tissues like bone mineral density and tiny blood vessels respond alongside the enlarging muscle fibres.

Purity & Handling Note: Verify 99%+ HPLC purity and complete TFA salt removal on your batch certificate before introducing a bacteriostatic reconstitution solution, and store the mixed vial strictly between 2°C and 8°C. Gently swirl rather than shake the glass so the large ActRIIB fusion protein retains its folded three-dimensional binding shape.

Comparison of Myostatin and ActRIIB Signalling Inhibitors in Published Studies

CompoundMolecular ClassPrimary TargetsKey Observations in Laboratory Models
ACE-031 (Ramatercept)Soluble ActRIIB-Fc fusion decoy receptorMyostatin (GDF-8), GDF-11, Activin A, BMP9, BMP10Robust skeletal muscle fibre hypertrophy and lean mass gains alongside off-target vascular signalling effects.
Follistatin-344 / FST-315Endogenous autocrine glycoproteinActivin A, Myostatin (GDF-8), GDF-11Pronounced local and systemic tissue remodelling with broad pituitary and reproductive hormone interactions.
Bimagrumab (BYM338)Monoclonal anti-ActRII antibodyMembrane-bound ActRIIA and ActRIIB receptorsBlocks receptor docking directly on the cell surface, increasing lean tissue volume and reducing adipose mass.
Domagrozumab / StamulumabNeutralising anti-myostatin antibodiesMyostatin (GDF-8) exclusivelyHighly selective target binding that avoids vascular side effects but produces smaller muscle mass changes than multi-ligand traps.
ACE-083Modified follistatin-Fc fusion proteinLocalised Myostatin, Activins, and GDF-11Engineered to tether to local extracellular matrix proteins, restricting muscle growth strictly to the studied muscle group.

Pairing Myostatin Blockers with Complementary Recovery Peptides

When investigators design experiments around tissue recovery and structural maintenance, they rarely look at myostatin blockade in isolation. Removing the brake on muscle growth is only half the equation; the cells still need raw energy, blood supply, and growth signals to build new tissue efficiently.

In laboratory models, scientists often compare or combine ActRIIB ligand traps with growth hormone secretagogues or insulin-like growth factor pathways, such as Ipamorelin or CJC-1295. While ACE-031 clears the path by silencing the Smad2/3 braking system, growth-factor signals push the accelerator by activating the Akt/mTOR pathway inside the cell. Observing both pathways together helps researchers see how cells handle maximum protein synthesis when both positive and negative regulators are adjusted at the same time.

Another common pairing in tissue remodelling research involves angiogenic and structural peptides like BPC-157 or TB-500. When muscle fibres expand rapidly after myostatin inhibition, the surrounding capillary network and connective fascia have to stretch and grow to keep up. Adding a compound that encourages endothelial cell migration and collagen organisation allows preclinical models to support the newly enlarged fibres with fresh oxygen and sturdy tendon attachments.

When setting up these multi-vial experiments, lab technicians pay close attention to how each lyophilised powder is prepared. While most standard chains dissolve easily in a bacteriostatic reconstitution solution, certain stubborn sequences require diluted acetic acid to achieve a completely clear liquid before mixing or testing. Keeping every amolist research peptide in its own properly pH-balanced vial prevents large fusion proteins like ACE-031 from clumping or losing their folded shape before the experiment even begins.

ACE-031: High-Affinity ActRIIB Ligand Traps and Myostatin Inhibition

Figure: ACE-031: High-Affinity ActRIIB Ligand Traps and Myostatin Inhibition

Protecting Large Fusion Proteins Through Cold Storage and Clean Chemistry

Unlike short chains made of ten or fifteen amino acids, ACE-031 is a large, folded dimeric fusion protein. Its ability to trap myostatin depends entirely on its three-dimensional shape. If the protein unfolds or clumps together inside the vial, the binding pocket collapses and the decoy receptor stops working in the lab.

This structural sensitivity is why checking for 99%+ purity via High-Performance Liquid Chromatography and mass spectrometry matters so much before starting a study. Cheaper batches often contain truncated peptide fragments, unlinked monomers, or leftover trifluoroacetic acid from the manufacturing wash. Residual trifluoroacetic acid is especially harsh on large proteins because it lowers the pH of the reconstituted liquid, stripping away delicate hydrogen bonds and causing the fusion protein to denature into useless cloudy flakes. Choosing batches that have undergone proper salt exchange and TFA removal protects the folded ActRIIB domain so that every measured level behaves predictably from week to week.

Temperature control is just as important as chemical cleanliness. Lyophilised cakes should go straight into a dedicated refrigerator held between two and eight degrees Celsius for routine storage, or minus twenty degrees Celsius for long-term archiving. Once mixed with a sterile bacteriostatic reconstitution solution, the liquid must stay at two to eight degrees Celsius and away from bright light.

Technicians should also avoid shaking the vial. Rolling the glass gently between the palms lets the powder dissolve without creating foam or shear stress that can tear the antibody-like hinge apart. address the vial with quiet, cold care, and the analytical readouts in your model will stay clean and consistent.

Frequently Asked Questions

Why do researchers search for ACE-031 and ActRIIB ligand traps?

Researchers investigate ACE-031 because it acts as a decoy receptor that traps myostatin before the protein can limit muscle growth. In published studies, blocking this biological brake allowed laboratory models to build greater lean tissue mass and strength. Scientists use it to characterise how muscle fibres regulate their own size.

What does the study timeline for ACE-031 show?

Early preclinical models showed rapid lean mass increases within weeks, but later investigations revealed off-target effects on blood vessels. Because the decoy receptor also bound related signalling proteins like BMP9, formal development paused around 2011. Today, it remains strictly an experimental tool used to analyse muscle signalling pathways in vitro.

Do laboratory protocols combine ACE-031 with other research compounds?

Laboratory protocols rarely combine ACE-031 with other compounds because its broad ligand-trapping action already alters multiple TGF-beta family signalling pathways at once. Introducing secondary growth factors makes it difficult for scientists to isolate which mechanism drives tissue remodelling. Researchers typically study this fusion protein alone to maintain clear, reliable data.

How should ACE-031 be stored to maintain high purity?

Lyophilised ACE-031 must be stored in a freezer at minus 20 degrees Celsius to keep its delicate fusion protein structure intact. Once mixed with a sterile bacteriostatic reconstitution solution, the liquid should stay refrigerated between 2 and 8 degrees Celsius and be analysed within a few days to prevent degradation.

Bibliography

  • Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102(50):18117-18122. View published research
  • Attie KM, Borgstein NG, Yang Y, et al. A single ascending-amount study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423. View published research
  • Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 protocol of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled preclinical trial. Muscle Nerve. 2017;55(4):458-464. View published research
  • Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol (1985). 2010;109(3):635-642. View published research
  • Sako D, Grinberg AV, Liu J, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem. 2010;285(27):21037-21048. View published research

⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.